You need to profile your AAV vector to ensure you are developing an effective gene therapy delivery system. In this mini-guide, learn about 4 technologies that give you a full stability profile of your gene therapy vector. From serotype assessment, to monitoring aggregate formation, to checking vector purity, to evaluating capsid assembly and genetic fill — these 4 technologies will help you identify the best formulation and multi-parameter quality control of AAVs, so you build more effective gene therapy vectors.
Ready to tackle your challenging stability characterizations?
Discover toolsSee more related content
1:41Prometheus Panta: The new gold standard for biologics characterization
Choosing the right stability characterization tool for your biologics research is a big commitment. You’re going to be screening and optimizing lots of candidates, and you’ll need data on thermal stab
8 biologics conferences you won’t want to miss in 2023
When you’re part of an industry that moves quickly, it’s important to keep up. You hear about biotherapeutics approvals, and big pharma news, but nothing matches the biologics conference experience.
4:51Four integrated technologies for Biologics developability assessment
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics
Use this downloadable list of 2023 biologics conferences to select which one to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
34:16Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and see a few examples of how DLS gives you deeper insights.
2:34Discover how 2bind applied multi-parameter characterization from a single experiment to find the optimal buffer for a vaccine antigen target.
Biologics developability: learn how Merck uses Prometheus Panta to create developability profiles for their mAbs
1:31How Janssen optimizes the stability of a therapeutic mAb
Discover how Janssen improved the stability of a promising prostate cancer targeting mAb. You’ll learn why it is important to optimize stability measurements of a therapeutic mAb.
NanoTemper Technologies arms gene therapy scientists with Static Light Scattering to sharpen their tool kit for development of AAVs
SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of Static Light Scattering (SLS) to their wildly successful Prometheus Panta, turning their instrument...
8 Gene Therapy conferences you should attend in 2022
With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...
14:07When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved. As part
5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved
As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...
25:08Overcome bottlenecks in viral vector manufacturing
The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developi
2:46Learn what attributes Prometheus users considered a must-have and how we made sure to preserve them when integrating and implementing new biophysical techniques. Prometheus Panta gives you the ability